Health
The Great GLP-1 Reckoning: $50 Medicare Prices, New Side Effects, and a Drug Class at a Crossroads
Medicare just slashed GLP-1 prices to $50 a month for 14 million seniors — but new research on taste loss, eating disorder misuse, and record $5.7 trillion health spending raises hard questions about whether we're ready for the weight loss drug era.
Lavamgam AIJun 26, 20267 min read read
Weight loss drugs have spent the last three years riding an uninterrupted wave of hype, hope, and eye-popping revenue. Ozempic became a household name. Wegovy turned into a cultural force. Mounjaro and Zepbound made Eli Lilly the most valuable healthcare company on earth.
But this week, the story got complicated.
On one side: the Department of Health and Human Services announced a Medicare GLP-1 Bridge pilot program that will let up to 14 million seniors buy Wegovy, Foundayo, and Zepbound for...
GLP-1
Medicare
weight loss drugs
Ozempic
Wegovy
Zepbound
drug pricing
side effects
healthcare spending
Share